SUPERNUS PHARMACEUTICALS, INC. Operating Leases, Rent Expense
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Operating Leases, Rent Expense of $3.60 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2020-02-28
- SUPERNUS PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2018-12-31 was $900.00K, a 12.50% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2018-09-30 was $900.00K, a 12.50% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2018-06-30 was $898.00K, a 79.60% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. operating leases, rent expense for the quarter ending 2018-03-31 was $900.00K, a 28.57% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2018 was $3.60M, a 33.33% increase from fiscal 2017.
- SUPERNUS PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2017 was $2.70M.
- SUPERNUS PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2015 was $2.60M, a 13.04% increase from fiscal 2014.
- SUPERNUS PHARMACEUTICALS, INC. operating leases, rent expense for fiscal 2014 was $2.30M, a 43.75% increase from fiscal 2013.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month | Operating Leases, Rent Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $1.80M derived: sum of 2 quarters · filed 2020-02-28 | $2.70M derived: sum of 3 quarters · filed 2020-02-28 | $3.60M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $900.00K 10-Q · filed 2018-11-09 | $1.80M derived: sum of 2 quarters · filed 2018-11-09 | $2.70M 10-Q · filed 2018-11-09 | $3.50M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-06-30 | $898.00K 10-Q · filed 2018-08-09 | $1.80M 10-Q · filed 2018-08-09 | $2.60M derived: sum of 3 quarters · filed 2020-02-28 | $3.40M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-03-31 | $900.00K 10-Q · filed 2018-05-10 | $1.70M derived: sum of 2 quarters · filed 2020-02-28 | $2.50M derived: sum of 3 quarters · filed 2020-02-28 | $3.00M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2017-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $1.60M derived: sum of 2 quarters · filed 2020-02-28 | $2.10M derived: sum of 3 quarters · filed 2020-02-28 | $2.70M 10-K · filed 2020-02-28 | |
| 2017-09-30 | $800.00K 10-Q · filed 2018-11-09 | $1.30M derived: sum of 2 quarters · filed 2018-11-09 | $1.90M 10-Q · filed 2018-11-09 | $2.70M derived: sum of 4 quarters · filed 2019-11-08 | |
| 2017-06-30 | $500.00K 10-Q · filed 2018-08-09 | $1.20M 10-Q · filed 2018-08-09 | $1.90M derived: sum of 3 quarters · filed 2019-11-08 | $2.60M derived: sum of 4 quarters · filed 2019-11-08 | |
| 2017-03-31 | $700.00K 10-Q · filed 2018-05-10 | $1.40M derived: sum of 2 quarters · filed 2019-11-08 | $2.10M derived: sum of 3 quarters · filed 2019-11-08 | $2.80M derived: sum of 4 quarters · filed 2019-11-08 | |
| 2016-12-31 | $700.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2019-11-08 | $1.40M derived: sum of 2 quarters · filed 2019-11-08 | $2.10M derived: sum of 3 quarters · filed 2019-11-08 | $2.70M 10-Q · filed 2019-11-08 | |
| 2016-09-30 | $700.00K 10-Q · filed 2017-11-09 | $1.40M derived: sum of 2 quarters · filed 2017-11-09 | $2.00M 10-Q · filed 2017-11-09 | $2.70M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | $700.00K 10-Q · filed 2017-08-03 | $1.30M 10-Q · filed 2017-08-03 | $2.00M derived: sum of 3 quarters · filed 2018-03-01 | $2.70M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | $700.00K 10-Q · filed 2017-05-09 | $1.30M derived: sum of 2 quarters · filed 2018-03-01 | $2.00M derived: sum of 3 quarters · filed 2018-03-01 | $2.60M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | $600.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $1.30M derived: sum of 2 quarters · filed 2018-03-01 | $1.90M derived: sum of 3 quarters · filed 2018-03-01 | $2.60M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $700.00K 10-Q/A · filed 2017-01-20 | $1.30M derived: sum of 2 quarters · filed 2017-01-23 | $2.00M 10-Q/A · filed 2017-01-20 | $2.70M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-06-30 | $600.00K 10-Q/A · filed 2017-01-23 | $1.20M 10-Q/A · filed 2017-01-23 | $2.00M derived: sum of 3 quarters · filed 2017-03-16 | $2.70M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2015-03-31 | $700.00K 10-Q/A · filed 2017-01-20 | $1.40M derived: sum of 2 quarters · filed 2017-03-16 | $2.10M derived: sum of 3 quarters · filed 2017-03-16 | $2.60M derived: sum of 4 quarters · filed 2017-03-16 | |
| 2014-12-31 | $700.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $1.40M derived: sum of 2 quarters · filed 2017-03-16 | $1.90M derived: sum of 3 quarters · filed 2017-03-16 | $2.30M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $700.00K 10-Q/A · filed 2017-01-20 | $1.20M derived: sum of 2 quarters · filed 2017-01-20 | $1.60M 10-Q/A · filed 2017-01-20 | ||
| 2014-06-30 | $500.00K 10-Q · filed 2015-08-07 | $1.00M 10-Q · filed 2015-08-07 | |||
| 2014-03-31 | $500.00K 10-Q · filed 2015-05-06 | ||||
| 2013-12-31 | $1.60M 10-K/A · filed 2017-01-20 | $1.02M 10-K · filed 2014-03-21 | |||
| 2012-12-31 | $900.00K 10-K · filed 2015-03-12 | $906.00K 10-K · filed 2013-03-15 | |||
| 2011-12-31 | $906.00K 10-K · filed 2014-03-21 | ||||
| 2010-12-31 | $918.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |